Advaxis (ADXS) announced that Kenneth A. Berlin has been appointed as President and CEO, effective April 23, 2018, and will also serve as a Director of the company. Interim CEO Anthony Lombardo will remain with Advaxis for a period of time to ensure a smooth transition to Berlin. In addition, Andres A. Gutierrez, M.D., Ph.D. has been named Executive Vice President, Chief Medical Officer, effective April 23, 2018. Advaxis also announced that CFO Sara Bonstein will be leaving the company as of April 30, 2018 to pursue a new professional opportunity. The company is actively engaged in the search for a new CFO, and will announce an interim appointment shortly. Berlin joins Advaxis from Rosetta Genomics (ROSG), where since 2009 he was President and CEO.